Dialog Box

New first-line treatment for patients with oesophago-gastric cancer

Two landmark studies on advanced oesophageal and gastric cancer were presented at the 2022 ASCO Gastrointestinal Cancers Symposium.

These studies were published in the Lancet and outlines the combination of chemo- and immuno-therapy as a new standard-of-care for patients with PD-L1 expression.

 The phase III KEYNOTE-590 study demonstrated that the combination of pembrolizumab and chemotherapy improved overall survival and progression-free survival in patients with advanced oesophageal adenocarcinoma, squamous cell carcinoma, or adenocarcinoma of the oesophagogastric junction. Similarly, the phase III CheckMate 649 study demonstrated that combining nivolumab and chemotherapy resulted in significant improvements in overall survival in patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma. These studies suggest a new treatment paradigm for patients with oesophago-gastric cancers.

Recently a patient access program and a product familiarisation program have been established for both drugs, which are available to Australian patients via Merck Sharp & Dohme (MSD) Australia or Bristol Myers Squibb (BMS) free of charge. 

Read the studies

Learn more about these studies here:

KEYNOTE-590CheckMate 649

17 May 2022
Category: News